ViewRay® Newsroom

ViewRay MRIdian System Receives CE Mark

World’s First Clinical MRI-Guided Radiation Therapy System Now Commercially Available in Europe

November 11, 2014

CLEVELAND, Ohio, November 11, 2014— ViewRay™, a privately held medical device company, announced today that its MRIdian™ \mə-ˈri-dē-ən\ system, the world’s first and only MRI-guided radiation therapy system, has received CE Mark (Conformité Européenne) approval. This milestone allows the company to deliver MRIdian systems throughout Europe and other regions that require the CE Mark. 

The MRIdian system uniquely provides continuous imaging during treatment so clinicians are able to see where the radiation dose is being delivered and adapt to changes and movement in the patient’s anatomy in real-time. The system tracks soft-tissues of the tumor directly, in fast planar images, then automatically compares the target to the plan and only allows treatment when the target is in range.

The MRIdian system allows clinicians to truly adapt the treatment plans every day to the patients’ internal changes. Utilizing MRI not only improves soft-tissue visualization, it eliminates X-ray exposure that is inherent in CT scans. 

“The European Union is the second largest radiation oncology market in the world. Receiving CE Mark is a momentous achievement and will undoubtedly fast track our conversations with medical institutions in Europe,” said Michael Brandt, senior vice president of sales at ViewRay Incorporated. “The MRIdian system represents the most advanced radiation therapy technology available, and we are excited to partner with cancer treatment leaders to make MRI-guided radiation therapy a standard for cancer care worldwide.”

“Being granted CE Mark opens the door for us to deliver the world’s only clinical MRI-guided radiation therapy platform to hundreds of medical facilities,” said Chris Raanes, president and CEO of ViewRay Incorporated. "With this milestone, we look forward to making MRI-guided radiation therapy a globally accessible treatment option for cancer patients.”

In May 2012, the MRIdian system received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is currently being used to treat patients at leading centers in the United States.


About ViewRay

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy. For more information, visit http://www.viewray.com.

ViewRay and MRIdian are trademarks of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.


Contact:

Michael Saracen
Senior Director, Marketing
ViewRay Incorporated
Phone: +1 440.703.3210, ext. 200
Email: media@viewray.com World’s First Clinical MRI-Guided Radiation Therapy System Commercially Available in Europe
Copyright 2017 © ViewRay. All rights reserved - KMCreative